s and Learning Outcomes / European Journal of Oncology Nursing 18S1 (2014) S1–S22 S21 of NEPA-treated patients reporting NIDL compared with PALO in the overall, nausea, and vomiting domains but also for several individual FLIE items (Table). % Patients with NIDL Nausea domain Vomiting domain

1Department of Nuclear Medicine, Department of Haematology 2Southampton University Hospitals NHS Trust, University of Southampton, Southampton, UK British Nuclear Medicine Society Oral and Poster Abstracts 2007

81 Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups T. de Witte (1), A. Hagemeijer (2), S. Suciu (3), A. Belhabri (4), M. Delforge (2), C. Aul (5), M. Aivado (6), D. Selleslag (7), H. Schouten (8), A. Ferrant (9), H. Biersack (10), S. Amadori (11), P. Muus (1), U. Jehn (12), F. Beeldens (3), J. Jansen (1), E. Hellstrom-Lindberg (13), T. Kovacsovics (14), U. Hess (15), P. Wijermans (16), G. Ossenkoppele (17), A. Gratwohl (18), J.-P. Marie (19), R. Willemze (20) (1)UMCN (Nijmegen, NL); (2)U.Z. Gasthuisberg (Leuven, B); (3)EORTC Data Center (Brussels, B); (4)Hopital Herriot (Lyon, F); (5)Dept Hematology (Duisburg, D); (6)University Hospital (Duesseldorf, D); (7)Academic Hospital St Jan (Brugge, B); (8)University Medical Center (Maastricht, NL); (9)Clinique Universitaire St Luc (Brussels, B); (10)University Hospital (Essen, D); (11)Ospedale San Eugenio (Rome, I); (12)Klinikum Grosshadern (Munich, D); (13)Huddinge (Stockholm, S); (14)Centre Hospitalier Vaudois (Lausanne, CH); (15)Kantonsspital St Gallen (St. Gallen, CH); (16)Leijenburg Hospital (The Hague, NL); (17)Academic Hospital (Amsterdam, NL); (18)Kantonsspital (Basel, CH); (19)Hotel-Dieu (Paris, F); (20)LUMC (Leiden, NL)

We report the results of a phase I clinical study using a radiolabelled murine anti-CD66 IgG1 monoclonal antibody (TheraPharm GmbH) as part of the transplant conditioning schedule for patients receiving either autologous or allogeneic stem cell transplants (SCT) for myeloma or acute myeloid leukaemia. This was a radiation dose escalation study using increasing doses of yttrium-90 (Y-90) as the therapeutic radionuclide. A total of eighteen patients have been treated over four Y-90 radiation dose levels. All patients received an initial infusion of indium-111 (In-111)-labelled anti-CD66 for biodistribution and dosimetry determination. If favourable dosimetry was demonstrated, patients went on to receive the therapy dose of radiation, the dose of Y-90 infused calculated from the patient's body weight. The Y-90 dose levels were as follows: 5, 10, 25 and 37.5MBq /kilogram (lean) body weight.

s of the 31st Annual Meeting of the British Nuclear Medicine Society, Manchester, UK, 29 April to 1 May 2003 - POSTER PRESENTATIONS